Luokang Bio Responds to Market Misunderstanding: Strategic Cooperation with Eli Lilly in New Drug R&D

LightningPacketLoss · 2026-03-25T10:03:47+00:00

Luokang Bio announced that its strategic cooperation agreement with Eli Lilly has become effective as of March 24, 2026, and received early approval from the Federal Trade Commission. The company clarified media misunderstandings, stating it has no intention to conduct an acquisition, and reminded shareholders to rely on official announcements.

LightningPacketLoss

2026-03-25 10:03:47

Abstract generation in progress

On March 25, Cinda Biotech announced that the company signed a strategic cooperation agreement with Eli Lilly and Company on February 8, 2026, to promote the development of new drugs in oncology and immunology fields (“the Announcement”). Unless the context otherwise requires, the terms used in this announcement shall have the same meanings as those defined in the Announcement.

The company’s board of directors hereby announces that the company has received prior approval from the Federal Trade Commission, and all conditions precedent for the strategic cooperation agreement between Eli Lilly and Cinda Biotech have been satisfied. The strategic cooperation agreement became effective on March 24, 2026.

The announcement mentions that some media incorrectly interpreted the agreement’s effectiveness as an acquisition of the company. The company clarifies that it has not and does not intend to carry out such a transaction. The company reminds shareholders and interested investors to rely on official announcements and not on market rumors.

(Cinda Biotech Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.